1 association between periodontal disease temporomandibular disorders and rheumatoid arthritis among patients visiting rheumatology centers in bengaluru city: a cross-sectional study

2 effect of isolated soy protein on prevention of rheumatoid arthritis in collagen- induced rats

3 The Relation between Toxocariasis and Toxoplasmosis co-infection and the presence of Rheumatoid Factor (RF) in people with hydatidosis in Southwestern Iran, from 2013 to 2018.

4 Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis.

5 Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.

6 High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.

7 Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.

8 Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk.

9 PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population.

10 Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13.

11 A Comparative Study of Interleukin 6, Inflammatory Markers, Ferritin, and Hematological Profile in Rheumatoid Arthritis Patients with Anemia of Chronic Disease and Iron Deficiency Anemia

12 Galectin-1, -4, and -7 Were Associated with High Activity of Disease in Patients with Rheumatoid Arthritis

13 Concordance between the Different Cardiovascular Risk Scores in People with Rheumatoid Arthritis and Psoriasis Arthritis

14 Medication Adherence and Coping Strategies in Patients with Rheumatoid Arthritis: A Cross-Sectional Study

15 Occipital and external acoustic meatus to axis angle: a useful predictor of oropharyngeal space in rheumatoid arthritis patients with atlantoaxial subluxation.

16 Association between plasminogen activator inhibitor‑1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis : A meta-analysis.

17 QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS - A PRELIMINARY STUDY.

18 Vitamin D Receptor Polymorphism and DHCR7 Contribute to the Abnormal Interplay Between Vitamin D and Lipid Profile in Rheumatoid Arthritis

19 Renal function and cardiovascular risk in rheumatoid arthritis

20 Respiratory viral infections and the risk of rheumatoid arthritis.

21 Prevalence of methotrexate intolerance among patients with rheumatoid arthritis using the Arabic version of the methotrexate intolerance severity score.

22 Crosstalk between Fas and S1P<inf>1</inf> signaling via NF-kB in osteoclasts controls bone destruction in the TMJ due to rheumatoid arthritis

23 Assessment of interstitial lung disease among black rheumatoid arthritis patients.

24 Potential mechanisms linking periodontitis to rheumatoid arthritis.

25 Machine-learning based knowledge discovery in rheumatoid arthritis related registry data to identify predictors of persistent pain.

26 Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements.

27 Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.

28 Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis.

29 Polymorphisms in peptidylarginine deiminase associate with rheumatoid arthritis in diverse Asian populations: evidence from MyEIRA study and meta-analysis.

30 Effectiveness of subcutaneously administered methotrexate in patients with rheumatoid arthritis.

31 Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in Japan: multi-center retrospective descriptive study.

32 Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.

33 No increase in the risk of autism spectrum disorder in children born to mothers with systemic lupus erythematosus and rheumatoid arthritis

34 Investigation of the cytokine response to NF-ΚB decoy oligonucleotide coated polysaccharide based nanoparticles in rheumatoid arthritis in vitro models

35 Proteomics Approach for the Discovery of Rheumatoid Arthritis Biomarkers Using Mass Spectrometry.

36 Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis.

37 Nigella sativa fixed oil as alternative treatment in management of pain in arthritis rheumatoid.

38 Salivary gland involvement in rheumatoid arthritis and its relationship to induced oxidative stress

39 Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study.

40 Macrophage M1/M2 polarization and rheumatoid arthritis: A systematic review.

41 Clinico-genetic model to predict methotrexate intolerance in rheumatoid arthritis.

42 The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States.

43 First Validation of the Full PROMIS Pain Interference and Pain Behavior Item Banks in Patients with Rheumatoid Arthritis.

44 Сase Report of Acute Toxic Imatinib-induced Hepatitis in a Patient with Chronic Myeloid Leukemia, Sulfa Allergy, and Rheumatoid Arthritis.

45 Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis.

46 Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis.

47 An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis

48 Methotrexate Restores CD73 Expression on Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis Patients and May Contribute to Its Anti-Inflammatory Effect through Ado Production.

49 Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro

50 What potential do magnetic iron oxide nanoparticles have for the treatment of rheumatoid arthritis?

51 Synovial tissue quantitative proteomics analysis reveals paeoniflorin decreases LIFR and ASPN proteins in experimental rheumatoid arthritis.

52 Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis.

53 Effect of Moxibustion on HIF-1 and VEGF Levels in Patients with Rheumatoid Arthritis.

54 Dose-Dependent Efficacy of Gold Clusters on Rheumatoid Arthritis Therapy.

55 Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.

56 Occupational determinants for rheumatoid arthritis.

57 Korean Red Ginseng exhibits no significant adverse effect on disease activity in patients with rheumatoid arthritis: a randomized, double-blind, crossover study

58 Correction to: Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis (Pharmaceutical Research, (2020), 37, 2, (25), 10.1007/s11095-019-2752-y)

59 Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.

60 Rheumatoid Arthritis and Swine Influenza Vaccine: A Case Report

61 [Increased percentage and defective inhibitory function of CD4CD25FOXP3 T cells in synovial fluid of patients with rheumatoid arthritis].

62 Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39

63 Impact of pharmacist educational intervention on disease knowledge, rehabilitation and medication adherence, treatment-induced direct cost, health-related quality of life and satisfaction in patients with rheumatoid arthritis: study protocol for a randomized controlled trial.

64 One year in review 2020: novelties in the treatment of rheumatoid arthritis.

65 Clinical Improvements as Predictors of Improvements in Patient-Reported Outcomes: Post Hoc Analysis of a Randomized, Open-Label Study of Etanercept in Latin American Patients with Rheumatoid Arthritis.

66 Rituximab in routine care of severe active rheumatoid arthritis : A prospective, non-interventional study in Germany.

67 Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

68 Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis

69 Carbohydrate metabolism disorders in patients with rheumatoid arthritis and ankylosing spondylitis – impact of treatment

70 PERIOPERATIVE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS

71 Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.

72 Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a 'mix-and-match' approach?

73 The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis

74 Galantamine in rheumatoid arthritis: A cross talk of parasympathetic and sympathetic system regulates synovium-derived microRNAs and related pathogenic pathways.

75 Energy Conversion-Based Nanotherapy for Rheumatoid Arthritis Treatment.

76 The Relationship between Hematological Markers of Systemic Inflammation (Neutrophil-To-Lymphocyte, Platelet-To-Lymphocyte, Lymphocyte-To-Monocyte Ratios) and Ultrasound Disease Activity Parameters in Patients with Rheumatoid Arthritis

77 Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis.

78 Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis

79 A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

80 Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis

81 The Relationship between Hematological Markers of Systemic Inflammation (Neutrophil-To-Lymphocyte, Platelet-To-Lymphocyte, Lymphocyte-To-Monocyte Ratios) and Ultrasound Disease Activity Parameters in Patients with Rheumatoid Arthritis

82 Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis

83 Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

84 Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis

85 [Rheumatoid arthritis as a connective tissue disease]

86 Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.

87 [Rheumatoid arthritis in elderly people]

88 Diastolic dysfunction in rheumatoid arthritis patients with low disease activity

89 Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

90 The "Treat to Target" Approach to Rheumatoid Arthritis

91 Systemic Manifestations and Complications in Patients with Rheumatoid Arthritis

92 [Clinical and ultrasound assessment of the disease activity in patients with rheumatoid arthritis]

93 221 Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study

94 Cryptotanshinone induces reactive oxygen species‑mediated apoptosis in human rheumatoid arthritis fibroblast‑like synoviocytes

95 Gender Differences in Cardiovascular Risk Profile in Rheumatoid Arthritis Patients with Low Disease Activity

96 [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission]

97 221 Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study

98 Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity

99 Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

100 Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis

101 Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis

Keyword Connections

Journals

Research Groups

Bibliographies